📺 What you need to know about Omicron

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.

People with hypertension are at the greatest risk of developing serious cardiovascular diseases. A team of researchers at the Experimental and Clinical Research Center are now investigating whether probiotics in food supplements can support drug therapies or even delay the need to start them.

It borders on the miraculous how an entire animal emerges from a single egg cell. In order to understand the underlying molecular mechanisms, Markus Mittnenzweig is establishing the Computational and Developmental Biology Lab at the Max Delbrück Center.

People with Huntington’s disease lose control of their bodies and minds. The symptoms are caused by protein clumps in the nerve cells. Supported by a Marie Skłodowska-Curie Individual Fellowship, Andrea Quezada aims to create atomic models of these fibrils at the Max Delbrück Center.